201 related articles for article (PubMed ID: 19636007)
21. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population.
Kim IS; Kim DC; Kim HG; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Kim S; Lee GW
Cancer Genet Cytogenet; 2010 Jan; 196(1):31-7. PubMed ID: 19963133
[TBL] [Abstract][Full Text] [Related]
22. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy of conservative treatment of gastric lymphosarcoma].
Zvonkov EE; Kremenetskaia AM; Kravchenko SK; Makhinia VA; Kaplanskaia IB; Obukhova TN; Samoĭlova RS; Shevelev AA; Magomedova AU; Bariakh EA; Krasil'nikova BB; Gubkin AV; Iliushkina EA; Mar'in DS; Morozova AK; Kulikov SM; Gemdzhian EG; Vorob'ev AI
Ter Arkh; 2008; 80(7):18-26. PubMed ID: 18763589
[TBL] [Abstract][Full Text] [Related]
24. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains.
Yahalom J
J Clin Oncol; 2010 Sep; 28(27):4105-7. PubMed ID: 20713874
[No Abstract] [Full Text] [Related]
25. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
Ziepert M; Hasenclever D; Kuhnt E; Glass B; Schmitz N; Pfreundschuh M; Loeffler M
J Clin Oncol; 2010 May; 28(14):2373-80. PubMed ID: 20385988
[TBL] [Abstract][Full Text] [Related]
26. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
[TBL] [Abstract][Full Text] [Related]
27. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
28. ALK-positive diffuse large B-cell lymphoma.
Bubała H; Małdyk J; Włodarska I; Sońta-Jakimczyk D; Szczepański T
Pediatr Blood Cancer; 2006 May; 46(5):649-53. PubMed ID: 15852431
[TBL] [Abstract][Full Text] [Related]
29. Diffuse large B-cell lymphoma with fibrillary matrix.
Dargent JL; Meiers I; Lespagnard L; Ma Y; Dehou MF; Verhest A
Diagn Cytopathol; 2002 Oct; 27(4):223-6. PubMed ID: 12357500
[TBL] [Abstract][Full Text] [Related]
30. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
Visco C; Canal F; Parolini C; Andreoli A; Ambrosetti A; Krampera M; Lestani M; Pizzolo G; Chilosi M
Haematologica; 2006 May; 91(5):687-90. PubMed ID: 16670073
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
32. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
34. Improving outcomes for patients with diffuse large B-cell lymphoma.
Flowers CR; Sinha R; Vose JM
CA Cancer J Clin; 2010; 60(6):393-408. PubMed ID: 21030533
[TBL] [Abstract][Full Text] [Related]
35. An unresectable Klatskin's tumor?
Hartl J; Werner T; Schramm C
Gastroenterology; 2014 Jun; 146(7):e3-4. PubMed ID: 24780210
[No Abstract] [Full Text] [Related]
36. Prognostic factors of primary gastric diffuse large B cell lymphoma: a retrospective study of 75 cases in China.
Wu YX; Liu B; Chen L; Li JH; Chen SQ
Ann Hematol; 2013 Jun; 92(6):861-2. PubMed ID: 23238898
[No Abstract] [Full Text] [Related]
37. ALK-positive diffuse large B-cell lymphoma: report of three cases.
Lee HW; Kim K; Kim W; Ko YH
Hematol Oncol; 2008 Jun; 26(2):108-13. PubMed ID: 18220322
[TBL] [Abstract][Full Text] [Related]
38. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma.
Kim DH; Baek JH; Chae YS; Kim YK; Kim HJ; Park YH; Song HS; Chung JS; Hyun MS; Sohn SK
Leukemia; 2007 Oct; 21(10):2227-30. PubMed ID: 17554383
[No Abstract] [Full Text] [Related]
39. Conjunctival lymphoma in a child.
Waisbourd M; Leibovitch I; Sayar D; Elhasid R
Cornea; 2011 May; 30(5):598-9. PubMed ID: 21107252
[TBL] [Abstract][Full Text] [Related]
40. Anaplastic large cell lymphoma: redefining its morphologic spectrum and importance of recognition of the ALK-positive subset.
Chan JK
Adv Anat Pathol; 1998 Sep; 5(5):281-313. PubMed ID: 10021895
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
